Drug Profile
Research programme: adoptive T-cell receptor-based immunotherapies - Zelluna Immunotherapy
Alternative Names: TCR Adoptive Cell Therapy - Zelluna Immunotherapy; TCR-based immunotherapies - Zelluna Immunotherapy; TCR-T-XLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Zelluna Immunotherapy
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Cancer in Norway (Parenteral)
- 19 Nov 2019 Zelluna Immunotherapy plans a clinical trial for Cancer in 2020
- 14 Mar 2019 Targovax grants a freedom-to-operate (FTO) license to Zelluna Immunotherapy for its intellectual property relating to mutant Ras T cell receptor technology